Business Wire

TSURUMI-BREWING

Share
Sales to Begin of Tsurumi Brewing's SUSHI SAKE—A Sake Expressly for Sushi, Japan's Culinary Gift to the World

Founded in 1873, Tsurumi Shuzou Co., Ltd. (hereinafter, Tsurumi Brewing ) have developed SUSHI SAKE Kamitsuru Junmai Daiginjo (junmai means it is made with only rice products and no added alcohol, and daiginjo refers to the fact that the rice has been milled to fifty percent or less of its weight during the process), based on the concept of having a Japanese sake to go with sushi, in conjunction with the boom we are currently seeing in sake popularity outside of Japan. Sales have begun in November of 2015.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151130005179/en/

Product info: http://www.tsurumi-jp.com/sushi_sake/en

Priced at ¥12,000 per bottle, SUSHI SAKE Kamitsuru Junmai Daiginjo, a Sake for Sushi

Tsurumi Brewing, a company that produces and sells sake, began sales of SUSHI SAKE Kamitsuru Junmai Daiginjo in November, working from the notion that sake could serve to improve the wonderful taste of sushi, beloved world-wide, and representative of Japan’s food culture.

We designed SUSHI SAKE to hold back the raw odors unique to the fish used in sushi on your palette while paying particular attention to the balance for the earthier, umami flavors. By offering a crisp finishing tone, you will find it goes very well with sushi by preparing you for the next bite.

Developed by a Venerable Japanese Sake Brewer

Development of SUSHI SAKE occurred at Tsurumi Brewing, an esteemed, established sake brewery in Aichi Prefecture. Tsurumi Brewing began its history in 1873 when founder Teizo Tsurumi, who had been working with dyed goods, opened a sake brewery.

We maintain the traditional methods of production that have been handed down in the Tsushima area, striving to protect the merits of production by hand in the process. At the same time, we are also working to harmonize these methods with more modern systems of quality control and ingenuity, as we strive to create even better sake, and drawing out the depths of flavor inherent in the rice to impart a truly rich taste.

Completed After Trial and Error Under the Tutelage of the Master of a Long-established Restaurant, Founded in 1934

When it came to put the finishing touches on SUSHI SAKE, we turned to the advice of a respected, long-established restaurant, having many fans across Japan. This, we knew, would be critical in our process for the sixth generation of the Tsurumi family who currently operates the company that was founded in 1873.

Using only Yamadanishiki rice, we mill it down to forty percent of its weight. We draw water from an underground source of the Kiso River. Fermentation of the sake occurs at the optimal low temperatures found during the peak of winter, and it is the skill and dedication of the chief brewer, applied slowly over time, that results in the highest quality sake. You will enjoy a subtly rich taste.

Plans to Expand Sales from Shanghai and Hong Kong to Paris and New York

At present, SUSHI SAKE is available at the most established restaurants and department stores in Japan, but starting in December, there will be tastings planned, along with Japanese food, at restaurants in Italy. Moving forward, we plan to expand exports to Shanghai, Hong Kong, Paris, and New York. We will also be increasing availability at restaurants within Japan, as well as sales at department stores and online. Other varieties of SUSHI SAKE in addition to Junmai Daiginjo will be available for sale as well, including Daiginjo, Junmai Ginjo, Ginjo, and Junmai (ginjo refers to the fact that the rice has been milled to 60% of its weight or less).

 

Product Facts

Name  

:

  SUSHI SAKE Kamitsuru Junmai Daiginjo
Price

:

¥12,000 (pre-tax)
Volume

:

1,800 ml
Ingredients

:

Rice, rice malt
Percent alcohol

:

15.5%
Rice used

:

100% Yamadanishiki
Milling degree

:

40%
 

Corporate Overview

Name  

:

  Tsurumi Shuzou Co., Ltd.
Address

:

46 Asahi, Hyaku-cho, Tsushima City, Aichi Prefecture
Representative

:

Masahito Tsurumi
Capitalization

:

¥10 million
Established

:

1873
Incorporation

:

December 1949
Business

:

Production, wholesaling, and retailing of sake, mirin, liqueurs, shochu products, fruit wines, fortified wines, miscellaneous liquors, spirits, beer, and vinegar
Website

:

http://www.tsurumi-jp.com/sushi_sake/en

Contact:

TSURUMI SHUZOU Co., Ltd.
Masahito Tsurumi, +81-567-31-1141
tsurumi@tsurumi-jp.com
Fax: +81-567-32-0586

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye